|
Table of Contents 1. Analyst View 2. Research Methodology 3. Tests Available in the US NIPT Market 3.1 MaterniT21 3.2 Verifi 3.3 Panorama 3.4 Harmony 4. Current Technologies in the Market 5. Association of Down’s syndrome Risk to Fetus with Mother's Age 6. Demographics Outlook 6.1 Population Demographics 6.2 Number of Births: Current and Future
6.2.1 By Age Group
6.2.2 By State 6.3 Disease Demographics 7. US NIPT - Potential Market (2014 & 2020) 8. US NIPT Market Projections to 2020 8.1 Market Size and Forecast 8.2 Market Share of Players 9. Regulatory Insight 9.1 Current Regulatory Scenario 9.2 Regulatory Authority Perspective 9.3 Diagnostic Test Provider Perspective 9.4 ACOG Opinion 9.5 Consumers’ Perspective 9.6 Analyst Inputs 10. Reimbursement Scenario for US NIPT Market 11. Competitive Assessment 11.1 Ariosa Diagnostics
11.1.1 Business Overview
11.1.2 Strengths and Weaknesses
11.1.3 Recent Developments 11.2 Sequenom
11.2.1 Business Overview
11.2.2 Strengths and Weaknesses
11.2.3 Recent Developments 11.3 Verinata
11.3.1 Business Overview
11.3.2 Strengths and Weaknesses
11.3.3 Recent Developments 11.4 Natera
11.4.1 Business Overview
11.4.2 Strengths and Weaknesses
11.4.3 Recent Developments
List of Figures
Figure 3-1: Verifi Test Validation Results
Figure 3-2: Panorma Test Validation Results
Figure 3-3: Harmony Test Validation Results
Figure 5-1: Risk of Down's syndrome with Rise in Maternal Age
Figure 6-1: Population (Million), 2014-2020
Figure 6-2: Male-Female Ratio (%), 2014
Figure 6-3: Number of Births (Million), 2010-2014
Figure 6-4: Number of Births (Million), 2014-2020
Figure 7-1: Number of Births by Mother's Risk of Down's syndrome (%), 2014
Figure 7-2: High Risk NIPT Potential Market (Million US$), 2014 & 2020
Figure 7-3: Medium Risk NIPT Potential Market (Million US$), 2014 & 2020
Figure 8-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2014-2020
Figure 8-2: NIPT Market Penetration in High Risk Category (2014)
Figure 8-3: Share of Players in Number of NIPT Tests Performed (2014)
Figure 8-4: Share of Players in NIPT Market (2014)
Figure 8-5: Forecast for Share of Players in Number of NIPT Tests Performed (2020)
Figure 8-6: Forecast for Share of Players in NIPT Market (2020)
Figure 9-1: Laboratorians' Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)
List of Tables
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 4-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma
Table 6-1: Births by Women Age-Group (%), 2014-2020
Table 6-2: Top Ten States by Number of Births (2012 & 2013)
Table 6-3: Prevalence of Chromosomal Abnormalities
Table 9-1: Inter-comparison of CLIA and FDA Regulatory Pathway
Table 10-1: Comparative Analysis of Tests Available in US NIPT Market
|
현재위치 : 
